Innovacell Inc, (Head Office: Shinagawa-ku, Tokyo; Representatives: Colin Lee Novick and Jason David Sieger), a company dedicated to improving patients` health and quality of life (QOL) through cell therapy for the treatment of fecal and urinary incontinence, is pleased to announce the publication of articles provided by our company on the topic of fecal incontinence. (With permission from the publishers, copies of the articles are displayed.)
Published Articles
- Living Kobe East Issue No. 1558 (April 25, 2025) – Doctor’s Advice!
“Fecal incontinence is a treatable condition – Don’t suffer alone, consult a medical professional” (Dr. Ryo Okamoto, Chief Surgeon, Department of Gastrointestinal Surgery, Meiwa Hospital) - Living Nishinomiya / Takarazuka / Ashiya Issue No. 2106 (April 25, 2025) – Doctor’s Advice!
“Fecal incontinence is a treatable condition – Don’t suffer alone, consult a medical professional” (Same content as the article published in Living Kobe Higashi) - Living Fukuoka April 26, 2025 Issue – Doctor’s Voice
“Fecal incontinence is a treatable symptom! Don’t give up—visit your local proctologist”
(Dr. Toshihiro Noake, Director, Kurume Hospital, Takano Medical Corporation)
About Innovacell Co., Ltd.
Our company originated as a regenerative medicine startup spun out from the Medical University of Innsbruck in Austria. Innovacell Inc. was established in Japan in 2021 as the parent company of the Austrian entity. Our group aims to enhance health and QOL through the commercialization of regenerative medicine. We are currently engaged in research and development of regenerative medical products to treat urge or passive fecal incontinence and stress urinary incontinence.
Our most advanced pipeline product, ICEF15, utilizes the patient’s own myoblasts to regenerate muscle through local administration, aiming for a fundamental treatment of urge fecal incontinence. We are currently conducting a Phase III international joint clinical trial (Fidelia Study) in 10 European countries and Japan.
Additionally, our group has successfully completed multiple clinical trials in Europe, including two late Phase II studies: ICEF15 (for urge fecal incontinence) and ICES13 (for stress urinary incontinence).